278 related articles for article (PubMed ID: 34613870)
1. Safety of Japanese encephalitis vaccines.
Hu YL; Lee PI
Hum Vaccin Immunother; 2021 Nov; 17(11):4259-4264. PubMed ID: 34613870
[TBL] [Abstract][Full Text] [Related]
2. Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis.
Wang SY; Cheng XH; Li JX; Li XY; Zhu FC; Liu P
Hum Vaccin Immunother; 2015; 11(6):1418-25. PubMed ID: 25915588
[TBL] [Abstract][Full Text] [Related]
3. Current recommendations for the Japanese encephalitis vaccine.
Chen HL; Chang JK; Tang RB
J Chin Med Assoc; 2015 May; 78(5):271-5. PubMed ID: 25841620
[TBL] [Abstract][Full Text] [Related]
4. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.
Erra EO; Kantele A
Expert Rev Vaccines; 2015; 14(9):1167-79. PubMed ID: 26162529
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
[TBL] [Abstract][Full Text] [Related]
6. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
[TBL] [Abstract][Full Text] [Related]
8. Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis.
Furuya-Kanamori L; Xu C; Doi SAR; Clark J; Wangdi K; Mills DJ; Lau CL
Vaccine; 2021 Jul; 39(32):4429-4436. PubMed ID: 34175128
[TBL] [Abstract][Full Text] [Related]
9. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
10. Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: A review of safety and tolerability studies.
Ginsburg AS; Meghani A; Halstead SB; Yaich M
Hum Vaccin Immunother; 2017 Oct; 13(10):2222-2231. PubMed ID: 28841362
[TBL] [Abstract][Full Text] [Related]
11. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Fischer M; Lindsey N; Staples JE; Hills S;
MMWR Recomm Rep; 2010 Mar; 59(RR-1):1-27. PubMed ID: 20224546
[TBL] [Abstract][Full Text] [Related]
12. Product review on the JE vaccine IXIARO.
Firbas C; Jilma B
Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812
[TBL] [Abstract][Full Text] [Related]
13. Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.
Turtle L; Tatullo F; Bali T; Ravi V; Soni M; Chan S; Chib S; Venkataswamy MM; Fadnis P; Yaïch M; Fernandez S; Klenerman P; Satchidanandam V; Solomon T
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005263. PubMed ID: 28135273
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
[TBL] [Abstract][Full Text] [Related]
15. Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.
Hegde NR; Gore MM
Hum Vaccin Immunother; 2017 Jun; 13(6):1-18. PubMed ID: 28301270
[TBL] [Abstract][Full Text] [Related]
16. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB; Vrati S
Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
[TBL] [Abstract][Full Text] [Related]
17. Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia.
Islam N; Lau C; Leeb A; Mills D; Furuya-Kanamori L
Hum Vaccin Immunother; 2022 Dec; 18(1):2020573. PubMed ID: 35254947
[TBL] [Abstract][Full Text] [Related]
18. Allergic reactions to Japanese encephalitis vaccine.
Plesner AM
Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
[TBL] [Abstract][Full Text] [Related]
19. Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices.
Hills SL; Walter EB; Atmar RL; Fischer M;
MMWR Recomm Rep; 2019 Jul; 68(2):1-33. PubMed ID: 31518342
[TBL] [Abstract][Full Text] [Related]
20. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
